10月26日，BioNTech SE夜盘上涨5.5%，报92.96美元，成交额541.0美元。
推动异动的消息面，主要是公司近日宣布与吉利德科学合作，评估其实验药物pumitamig与Trodelvy联合作为晚期三阴性乳腺癌一线治疗方案。
根据披露，BioNTech计划在获得监管批准后调整全球Ⅲ期ROSETTA Breast-01试验，以Trodelvy替代化疗；公司继续主导并赞助试验，吉利德负责供应药物。这将成为首个将pumitamig与抗体偶联药物联用的全球Ⅲ期研究，显示其肿瘤管线推进仍在延续。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.